23rd August, 2019 - Press notes
Preliminary results from a clinical trial led by the Hospital del Mar Medical Research Institute and Hospital del Mar show a good response to the drug in patients with metastatic tumours that did not respond to the usual treatment. It involves an inhibitor of a dual protein, mTORC1/2, which is key in tumour growth. The researchers had already demonstrated its effectiveness in in vitro and mouse models, in a study published in the journal Molecular Cancer Research.
10 July, 2019 - Press notes
Researchers from the Hospital del Mar Medical Research Institute have been able to prevent the growth of tumours and eliminate them using a treatment that combines chemotherapy with a protein inhibitor to prevent the repair of damaged DNA in cancer cells. The feasibility of this approach has been tested in mice, studying the evolution of metastatic colon tumours from human patients. The use of this drug combination will now be studied in human patients. The research has been published in the journal Molecular Cell.
28 June 2019 - Press notes
Study published in Cancer Immunology Research
Ageing of NK lymphocytes (Natural killer cells) in HER2-positive breast cancer patients can predict the success or failure of targeted treatments. A blood sample is sufficient for detecting this possible resistance biomarker that, if validated, will allow the therapy to be adapted when the disease is diagnosed. This is the first study to identify NK lymphocyte ageing as a parameter that may condition their anti-tumour potential.20 May, 2019 - Press release
Barcelona Supercomputing Center, UPC and Institut Hospital del Mar d'Investigacions Mèdiques organize the first Advances in Computational Biology conference will bring together researchers working on systems biology, omics technologies, artificial intelligence and high-performance computing (HPC) with applications to biology from both the public and the private sectors. The conference will be held November 28-29 in La Pedrera (Barcelona).
4 April, 2019 - Press release
A study by doctors and researchers at Hospital del Mar and the Hospital del Mar Medical Research Institute, in collaboration with Johns Hopkins University in the United States, reveals that osteoporosis problems in HIV sufferers are caused by infection and not antiretroviral treatment. The discovery modifies how the problem of bone fracture is addressed in these patients, leading the way to studies of new drugs that complement treatments for combatting the virus. The results have been obtained thanks to a bone quality measurement technique that applies a clinical protocol developed at Hospital del Mar and which several centres in other countries have already shown interest in.
14 March, 2019 - Press notes
Hospital del Mar is the first centre in Spain and one of the first in Europe to use laser technology to treat epilepsy and brain tumours safely, quickly and in a minimally invasive way. So far, three successful operations have been performed on epilepsy sufferers. In just 48 hours, they were discharged and were able to go home. The centre will operate on 10 patients each year using this pioneering technique.
February 22, 2019 - Press notes
Researchers from the Hospital del Mar and Hospital del Mar Medical Research Institute (IMIM) have led a study verifying the importance of the presence of a specific type of lymphocyte in the success of anti-tumour treatments in patients with HER2-positive breast cancer.
This is the first time that the role of these immune system cells in treatment response has been verified with patient samples. The role HLA molecules play in obtaining good results has also been determined.
This work leads the way to finding new methods for reinforcing both existing treatments and those in a trial phase, including the possibility of transplanting NK cells from healthy patients into cancer sufferers. The study has been published in the journal Clinical Cancer Research
19th November, 2018 -
Study published in Circulation Research
Patients with certain variants of the PATJ gene have less ability to recover after suffering a stroke. 7 out of every 10 patients who have this genetic variation are left with serious consequences three months after having a stroke, compared to less than half of sufferers who do not present this variation. These variants could indicate targets for future treatments that improve stroke prognosis, and enable personalised rehabilitation strategies. This has been revealed by the first multicentre study in this field, using data from more than 2,000 individuals and involving 12 centres around the world. The work was led by researchers from the Hospital del Mar Medical Research Institute as well as doctors from Hospital del Mar, with Genestroke Consortium groups and the collaboration of the International Stroke Genetics Consortium. The study was funded by La Marató de TV3.October 29th 2018 -
The study, published in the journal Cancer Research, shows the pivotal role of the enzyme USP27X in the control of the proliferation, invasion and formation of breast cancer metastasis and opens new pathways to the development of anti-tumour drugs.
2 August 2018 -
Study published in Nature Communications
Researchers from the Hospital del Mar Medical Research Institute, with the support of IDIBELL and CIBERONC, have discovered that inhibiting the Jagged 1 protein prevents tumour growth in mice. This protein plays a key role in the development of the disease, because it activates the cell signal that allows cancer cells to grow and divide. The discovery leads the way to the development of a therapy for treating this type of pathology in humans, the second leading cause of cancer-related death in Western countries.
This site complies with the HONcode standard for trustworthy health information: 
Parc Salut Mar
Passeig Marítim 25-29 Barcelona 08003
See location on Google maps
Phone: 93 248 30 00 · Fax: 93 248 32 54
Information request
© 2006 - 2024 Parc de Salut Mar · Legal notice and Privacy Police | Cookie Policy | Accessibility
